8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Jan 29, 2026·SEC
Summit Therapeutics Inc.(SMMT)Earnings, Financials & Key Ratios
SMMT•NASDAQ
$17.85
$13.84B mkt cap·Price updated May 6, 2026
AboutSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$1.09B-463.6%
- Net Income-$1.08B-387.8%
- EPS (Diluted)-1.44-364.5%
- ROE-206.1%-117.2%
- ROIC-220.17%-180.3%
- Debt/Equity0.03+70.8%
SMMT Key Insights
Summit Therapeutics Inc. (SMMT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 82.9% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 20.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SMMT Price & Volume
Summit Therapeutics Inc. (SMMT) stock price & volume — 10-year historical chart
Loading chart...
SMMT Growth Metrics
Summit Therapeutics Inc. (SMMT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-400.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-376.62%
Return on Capital
10 Years-72.79%
5 Years-84.63%
3 Years-99.9%
Last Year-204.17%
SMMT Recent Earnings
Summit Therapeutics Inc. (SMMT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)
Q2 2026Latest
Apr 30, 2026EPS
$0.24
Est $0.27
+10.9%
Revenue
—
Est $54,420
Q1 2026
Feb 23, 2026EPS
$0.29
Est $0.10
-182.5%
Revenue
—
Est $57M
Q4 2025
Oct 20, 2025EPS
$0.31
Est $0.18
-76.4%
Revenue
—
Est $77M
Q3 2025
Aug 11, 2025EPS
$0.76
Est $0.09
-736.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.24vs $0.27+10.9% | —vs $54,420 |
| Q1 2026 | Feb 23, 2026 | $0.29vs $0.10-182.5% | —vs $57M |
| Q4 2025 | Oct 20, 2025 | $0.31vs $0.18-76.4% | —vs $77M |
| Q3 2025 | Aug 11, 2025 | $0.76vs $0.09-736.9% | — |
Based on last 12 quarters of dataView full earnings history →
SMMT Peer Comparison
Summit Therapeutics Inc. (SMMT) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 29.76B | 151.07 | -25.39 | -69.35% | 0.10 | |||
 TNGX | 3.21B | 23.62 | -27.15 | 48.29% | -162.85% | -50.3% | 0.10 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 KRYS | 8.5B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 2.22% | 0.01 |
 EXEL | 12.37B | 48.70 | 17.52 | 6.98% | 35.08% | 40.21% | 6.83% | 0.08 |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 |
Compare SMMT vs Peers
Summit Therapeutics Inc. (SMMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SMMT Income Statement
Summit Therapeutics Inc. (SMMT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14.17M | 57.09M | 632.02K | 860K | 1.81M | 704.29K | 0 | 0 | 0 | 0 |
| Revenue Growth % | 391.94% | 302.94% | -98.89% | 36.07% | 110.35% | -61.07% | -100% | - | - | - |
| Cost of Goods Sold | 97.67K | 24.92K | 155.4K | 0 | 0 | 2.51M | 2.05M | 15.01M | 0 | 37K |
| COGS % of Revenue | 0.69% | 0.04% | 24.59% | - | - | 356.95% | - | - | - | - |
| Gross Profit | 14.17M▲ 0% | 56.39M▲ 298.0% | 611.87K▼ 98.9% | 860K▲ 40.6% | 1.81M▲ 110.3% | -1.81M▼ 200.1% | -2.05M▼ 13.3% | -15.01M▼ 632.0% | 0▲ 100.0% | -37K▲ 0% |
| Gross Margin % | 100% | 98.77% | 96.81% | 100% | 100% | -256.99% | - | - | - | - |
| Gross Profit Growth % | 391.94% | 298% | -98.91% | 40.55% | 110.35% | -200.06% | -13.26% | -632.05% | 100% | - |
| Operating Expenses | 54.13M | 51.67M | 23.24M | 54.05M | 88M | 77.49M | 87.69M | 226M | 1.09B | 1.22B |
| OpEx % of Revenue | 382.08% | 90.52% | 3676.54% | 6285.23% | 4864.29% | 11002.92% | - | - | - | - |
| Selling, General & Admin | 13.71M | 17.01M | 9.3M | 19.23M | 23.61M | 26.7M | 28.21M | 60.53M | 556.7M | 603.67M |
| SG&A % of Revenue | 96.8% | 29.8% | 1471.32% | 2236.28% | 1305.2% | 3791.03% | - | - | - | - |
| Research & Development | 41.01M | 49.07M | 32.78M | 52.02M | 85.35M | 52.35M | 59.47M | 150.78M | 537.67M | 619.03M |
| R&D % of Revenue | 289.43% | 85.95% | 5187.1% | 6049.3% | 4718.19% | 7432.96% | - | - | - | - |
| Other Operating Expenses | -587.47K | -14.41M | -18.85M | -17.2M | -20.97M | -1.56M | 0 | 14.69M | 0 | 0 |
| Operating Income | -25.83M▲ 0% | 5.39M▲ 120.9% | -42.76M▼ 893.6% | -71.65M▼ 67.5% | -86.19M▼ 20.3% | -79.3M▲ 8.0% | -89.74M▼ 13.2% | -211.3M▼ 135.5% | -1.09B▼ 417.9% | -1.03B▲ 0% |
| Operating Margin % | -182.31% | 9.44% | -6766.4% | -8330.93% | -4764.29% | -11259.77% | - | - | - | - |
| Operating Income Growth % | 16.86% | 120.86% | -893.56% | -67.54% | -20.29% | 7.99% | -13.16% | -135.47% | -417.91% | - |
| EBITDA | -25.43M | 7.34M | -41.37M | -69.64M | -83.73M | -78.04M | -89.58M | -194.16M | -1.09B | -1.03B |
| EBITDA Margin % | -179.48% | 12.86% | -6546.15% | -8098.02% | -4628.58% | -11080.44% | - | - | - | - |
| EBITDA Growth % | 17.95% | 128.87% | -663.58% | -68.33% | -20.23% | 6.8% | -14.79% | -116.74% | -463.58% | -310.64% |
| D&A (Non-Cash Add-back) | 400K | 1.95M | 1.39M | 2M | 2.46M | 1.26M | 155.32K | 17.15M | 146K | 121K |
| EBIT | -26.74M | 9.7M | -22.62M | -52.66M | -88.36M | -79.3M | -69.61M | -230M | -1.08B | -1.02B |
| Net Interest Income | 10.1K | -615K | -28.18K | -251K | -242K | -2.89M | -6.06M | 4.78M | 0 | 2.98M |
| Interest Income | 10.1K | 5K | 4.34K | 4K | 178.95K | 1.51M | 10.4M | 13.47M | 0 | 2.98M |
| Interest Expense | 0 | 620K | 32.52K | 255K | 281K | 4.4M | 16.46M | 8.69M | 0 | 0 |
| Other Income/Expense | 1.91M | 3.69M | 14.36M | 9.37M | -2.42M | -4M | -526.14M | 4.7M | 14.84M | 10.9M |
| Pretax Income | -23.92M▲ 0% | 9.08M▲ 138.0% | -28.41M▼ 412.8% | -62.27M▼ 119.2% | -88.6M▼ 42.3% | -83.31M▲ 6.0% | -615.87M▼ 639.3% | -221.31M▲ 64.1% | -1.08B▼ 387.8% | -1.21B▲ 0% |
| Pretax Margin % | -168.83% | 15.91% | -4494.82% | -7241.05% | -4897.84% | -11828.14% | - | - | - | - |
| Income Tax | -3.47M | -1.79M | 29.65K | -213K | -15.21M | -4.52M | -946K | 0 | 0 | 0 |
| Effective Tax Rate % | 14.53% | -19.66% | -0.1% | 0.34% | 17.16% | 5.43% | 0.15% | 0% | 0% | 0% |
| Net Income | -28.53M▲ 0% | 10.87M▲ 138.1% | -23.88M▼ 319.7% | -52.7M▼ 120.6% | -88.6M▼ 68.1% | -78.78M▲ 11.1% | -614.93M▼ 680.5% | -221.31M▲ 64.0% | -1.08B▼ 387.8% | -1.21B▲ 0% |
| Net Margin % | -201.39% | 19.04% | -3779.01% | -6127.56% | -4897.84% | -11185.94% | - | - | - | - |
| Net Income Growth % | -25.61% | 138.09% | -319.74% | -120.64% | -68.13% | 11.08% | -680.54% | 64.01% | -387.81% | -400.96% |
| Net Income (Continuing) | -20.16M | 10.87M | -23.99M | -52.7M | -88.6M | -78.78M | -614.93M | -221.31M | -1.08B | -1.21B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28▲ 0% | 0.11▲ 139.3% | -0.73▼ 763.6% | -0.76▼ 4.1% | -0.96▼ 26.3% | -0.41▲ 57.3% | -0.99▼ 141.5% | -0.31▲ 68.7% | -1.44▼ 364.5% | -1.56▲ 0% |
| EPS Growth % | 20% | 139.29% | -763.64% | -4.11% | -26.32% | 57.29% | -141.46% | 68.69% | -364.52% | -376.62% |
| EPS (Basic) | -0.31 | 0.11 | -0.73 | -0.76 | -0.96 | -0.41 | -0.99 | -0.31 | -1.44 | - |
| Diluted Shares Outstanding | 65.43M | 86.14M | 32.83M | 69.52M | 92.24M | 193.34M | 619.65M | 718.54M | 747.7M | 775.46M |
| Basic Shares Outstanding | 65.03M | 86.14M | 32.73M | 69.52M | 92.24M | 193.34M | 619.65M | 718.54M | 747.7M | 775.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SMMT Balance Sheet
Summit Therapeutics Inc. (SMMT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 35.84M | 61.29M | 62.11M | 66.42M | 97.31M | 656.71M | 189.71M | 423.75M | 720.3M | 616.6M |
| Cash & Short-Term Investments | 20.1M | 35.23M | 49.96M | 66.42M | 71.79M | 348.61M | 186.24M | 412.35M | 713.45M | 598.73M |
| Cash Only | 28.45M | 35.23M | 49.96M | 66.42M | 71.79M | 348.61M | 71.42M | 104.86M | 225.27M | 106.52M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 114.82M | 307.49M | 488.18M | 492.22M |
| Accounts Receivable | 9.33M | 7.95M | 318.12K | 10.19M | 8.63M | 6.12M | 848K | 557K | 0 | 0 |
| Days Sales Outstanding | 240.37 | 50.8 | 183.72 | 4.32K | 1.74K | 3.17K | - | - | - | - |
| Inventory | 0 | 0 | 0 | -11.71M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | -87.49K | 8.37M | 4.98M | 1.52M | 9.73M | 300.49M | 181K | 10.84M | 6.85M | 17.87M |
| Total Non-Current Assets | 25.58M | 17.09M | 13.34M | 36.08M | 16.06M | 7.46M | 13.24M | 11.81M | 30.88M | 31.26M |
| Property, Plant & Equipment | 1.15M | 807.92K | 1.2M | 1.28M | 3.48M | 5.08M | 6.06M | 7.4M | 21.68M | 21.06M |
| Fixed Asset Turnover | 12.37x | 70.66x | 0.52x | 0.67x | 0.52x | 0.14x | - | - | - | 0.00x |
| Goodwill | 3.51M | 2.38M | 1.15M | 2.03M | 2.01M | 1.8M | 1.89M | 1.86M | 2M | 1.97M |
| Intangible Assets | 20.93M | 13.91M | 7.71M | 11.52M | 10.4M | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 3.27M | 21.26M | 170K | 577K | 5.28M | 2.55M | 7.21M | 28.99M |
| Total Assets | 76.38M▲ 0% | 78.39M▲ 2.6% | 75.46M▼ 3.7% | 102.5M▲ 35.8% | 113.37M▲ 10.6% | 664.17M▲ 485.8% | 202.95M▼ 69.4% | 435.56M▲ 114.6% | 751.18M▲ 72.5% | 647.86M▲ 0% |
| Asset Turnover | 0.19x | 0.73x | 0.01x | 0.01x | 0.02x | 0.00x | - | - | - | 0.00x |
| Asset Growth % | 62.58% | 2.63% | -3.74% | 35.84% | 10.61% | 485.82% | -69.44% | 114.62% | 72.46% | 88.09% |
| Total Current Liabilities | 22.98M | 16.88M | 9.9M | 19.89M | 25.62M | 38.78M | 20.41M | 41.73M | 72.99M | 83.27M |
| Accounts Payable | 12.49M | 5.8M | 3.38M | 6.14M | 4.37M | 355K | 2.67M | 4.64M | 20.29M | 27.55M |
| Days Payables Outstanding | 46.68K | 84.95K | 7.93K | - | - | 51.54 | 474.86 | 112.76 | - | 229.53K |
| Short-Term Debt | 0 | 0 | 632.64K | 0 | 284.24K | 19.77M | 0 | 0 | 0 | 3.18M |
| Deferred Revenue (Current) | 13.89M | 0 | 1.17M | 8.37M | 7.94M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -60.29K | 10.62M | 32.33K | 1.71M | 641.22K | 6.3M | 9.5M | 33.33M | 17.21M | 52.54M |
| Current Ratio | 1.56x | 3.63x | 6.27x | 3.34x | 3.80x | 16.93x | 9.30x | 10.15x | 9.87x | 9.87x |
| Quick Ratio | 1.56x | 3.63x | 6.27x | 3.93x | 3.80x | 16.93x | 9.30x | 10.15x | 9.87x | 9.87x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.59M | 6.56M | 4.44M | 3.15M | 4.47M | 498.73M | 104.85M | 5.08M | 19.33M | 18.66M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 494.54M | 100M | 0 | 0 | 16.86M |
| Capital Lease Obligations | 962K | 0 | 330.21K | 75K | 1.69M | 2.76M | 3.29M | 3.45M | 17.5M | 22.64M |
| Deferred Tax Liabilities | 3.37M | 2.2M | 1.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.73M | 3.28M | 2.12M | 2.51M | 2.78M | 1.43M | 1.56M | 1.63M | 1.83M | 7.3M |
| Total Liabilities | 62.4M | 22.59M | 14.34M | 23.05M | 30.09M | 537.51M | 125.26M | 46.81M | 92.32M | 101.92M |
| Total Debt | 0 | 0 | 674.12K | 465K | 2.78M | 518.76M | 106.1M | 7.22M | 20.89M | 20.04M |
| Net Debt | -28.45M | -35.23M | -49.26M | -65.95M | -69.01M | 170.16M | 34.67M | -97.64M | -204.38M | -86.48M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.03x | 4.10x | 1.37x | 0.02x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | -4.80x | - | - | - | - | - | - | - | 0.08x |
| Interest Coverage | - | 15.65x | -695.65x | -206.49x | -314.45x | -18.02x | -4.23x | -26.48x | - | - |
| Total Equity | 13.98M▲ 0% | 55.8M▲ 299.2% | 61.12M▲ 9.5% | 79.45M▲ 30.0% | 83.28M▲ 4.8% | 126.65M▲ 52.1% | 77.69M▼ 38.7% | 388.75M▲ 400.4% | 658.86M▲ 69.5% | 545.93M▲ 0% |
| Equity Growth % | 420.14% | 299.18% | 9.53% | 30.01% | 4.82% | 52.07% | -38.66% | 400.37% | 69.48% | 104.93% |
| Book Value per Share | 0.21 | 0.65 | 1.86 | 1.14 | 0.90 | 0.66 | 0.13 | 0.54 | 0.88 | 0.70 |
| Total Shareholders' Equity | 9.88M | 55.8M | 61.12M | 79.45M | 83.28M | 126.65M | 77.69M | 388.75M | 658.86M | 545.93M |
| Common Stock | 736K | 2.1M | 507.29K | 826K | 980K | 2.11M | 7.02M | 7.38M | 7.75M | 7.76M |
| Retained Earnings | -132.95M | -99.8M | -119.46M | -214.74M | -299.55M | -378.33M | -993.26M | -1.21B | -2.29B | -2.48B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 23.91M | 0 | -3.6M | -3.79M | -2.2M | -1.89M | -2.45M | -2.29M | -2.54M | -2.63M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SMMT Cash Flow Statement
Summit Therapeutics Inc. (SMMT) cash flow — operating, investing & free cash flow history
| Line item | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.79M | -35.14M | -26.66M | -48.11M | -72.59M | -41.58M | -76.76M | -142.11M | -322.93M | -322.93M |
| Operating CF Margin % | -146.75% | -61.56% | -4218.72% | -5594.3% | -4012.55% | -5904.06% | - | - | - | - |
| Operating CF Growth % | -237.01% | -69.02% | 24.13% | -80.44% | -50.87% | 42.71% | -84.6% | -85.13% | -127.25% | -520.61% |
| Net Income | -15.42M | 6.6M | -23.88M | -52.7M | -88.6M | -78.78M | -614.93M | -221.31M | -1.08B | -1.21B |
| Depreciation & Amortization | 348.2K | 1.49M | 1.39M | 2M | 2.46M | 2.51M | 2.05M | 89K | -6.86M | -8.09M |
| Stock-Based Compensation | 2.27M | 6.22M | 542.05K | 1.29M | 12.8M | 12.15M | 14.11M | 50.98M | 732.42M | 794.12M |
| Deferred Taxes | 0 | 0 | 309.13K | 583K | 326K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.47M | 1.73M | -5.98M | 89.61K | 497K | 13.92M | 524.38M | 12.66M | 7.78M | 662.42K |
| Working Capital Changes | -11.47M | -51.18M | 955.98K | 619K | -67K | 8.62M | -2.37M | 15.48M | 23.32M | 35.36M |
| Change in Receivables | -8.95M | 0 | 4.63M | 212K | -1.14M | 975K | 4.53M | 535K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | -6.61M | 3.6M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -997.71K | 1.64M | -1.71M | -4.13M | 2.26M | 2.02M | 11.36M | 21.97M |
| Cash from Investing | -7.42M | -410.52K | -265.33K | -421K | -306K | -624K | -587.77M | -205.34M | -174.31M | -334.66M |
| Capital Expenditures | -678.01K | -163.94K | -265.33K | -421K | -306K | -624K | -128K | -139K | -657K | -480K |
| CapEx % of Revenue | 4.79% | 0.29% | 41.98% | 48.95% | 16.92% | 88.6% | - | - | - | - |
| Acquisitions | -6.76M | -251.82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 16.98K | 5.25K | 0 | 0 | 0 | 0 | -474.79M | -15.01M | 0 | 1 |
| Cash from Financing | 12.77M | 43.85M | 33.11M | 50.55M | 77.92M | 620.24M | 86.51M | 381.23M | 617.53M | 613.65M |
| Debt Issued (Net) | -128K | -368.55K | 0 | 0 | 0 | 520M | -24.69M | -100M | 0 | 0 |
| Equity Issued (Net) | 21.13M | 46.08M | 37.82M | 50M | 75M | 100.4M | 5M | 477.89M | 458.31M | 466.36M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -8.24M | -1.86M | -4.71M | 551K | 2.92M | -155K | 106.2M | 3.33M | 159.22M | 147.29M |
| Net Change in Cash | -11.27M▲ 0% | 8.86M▲ 178.6% | 6.76M▼ 23.8% | 2.58M▼ 61.9% | 5.37M▲ 108.7% | 576.82M▲ 10633.5% | -577.18M▼ 200.1% | 33.76M▲ 105.8% | 120.39M▲ 256.6% | -105.01M▲ 0% |
| Free Cash Flow | -21.47M▲ 0% | -35.31M▼ 64.5% | -15.83M▲ 55.2% | -48.53M▼ 206.6% | -72.89M▼ 50.2% | -42.21M▲ 42.1% | -76.89M▼ 82.2% | -142.25M▼ 85.0% | -323.59M▼ 127.5% | -384.53M▲ 0% |
| FCF Margin % | -151.54% | -61.85% | -2504.72% | -5643.26% | -4029.46% | -5992.66% | - | - | - | - |
| FCF Growth % | -242.51% | -64.45% | 55.16% | -206.58% | -50.2% | 42.1% | -82.17% | -85% | -127.49% | -121.58% |
| FCF per Share | -0.33 | -0.41 | -0.48 | -0.70 | -0.79 | -0.22 | -0.12 | -0.20 | -0.43 | -0.43 |
| FCF Conversion (FCF/Net Income) | 0.73x | -3.23x | 1.12x | 0.91x | 0.82x | 0.53x | 0.12x | 0.64x | 0.30x | 0.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 62.85K | 0 | 10.65M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 7K | 0 | 52K | 0 | 0 | 0 |
SMMT Key Ratios
Summit Therapeutics Inc. (SMMT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -593.72% | 31.15% | -40.86% | -74.98% | -108.89% | -75.05% | -601.85% | -94.9% | -206.1% | -291.24% |
| Return on Invested Capital (ROIC) | - | 132.64% | -198% | -424.31% | -465.43% | -38.24% | -32.9% | -78.56% | -220.17% | -220.17% |
| Gross Margin | 100% | 98.77% | 96.81% | 100% | 100% | -256.99% | - | - | - | - |
| Net Margin | -201.39% | 19.04% | -3779.01% | -6127.56% | -4897.84% | -11185.94% | - | - | - | - |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.03x | 4.10x | 1.37x | 0.02x | 0.03x | 0.03x |
| Interest Coverage | - | 15.65x | -695.65x | -206.49x | -314.45x | -18.02x | -4.23x | -26.48x | - | - |
| FCF Conversion | 0.73x | -3.23x | 1.12x | 0.91x | 0.82x | 0.53x | 0.12x | 0.64x | 0.30x | 0.32x |
| Revenue Growth | 391.94% | 302.94% | -98.89% | 36.07% | 110.35% | -61.07% | -100% | - | - | - |
SMMT SEC Filings & Documents
Summit Therapeutics Inc. (SMMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
SMMT Frequently Asked Questions
Summit Therapeutics Inc. (SMMT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Summit Therapeutics Inc. (SMMT) grew revenue by 0.0% over the past year. Growth has been modest.
Summit Therapeutics Inc. (SMMT) reported a net loss of $1.21B for fiscal year 2025.
Dividend & Returns
Summit Therapeutics Inc. (SMMT) has a return on equity (ROE) of -206.1%. Negative ROE indicates the company is unprofitable.
Summit Therapeutics Inc. (SMMT) had negative free cash flow of $384.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More SMMT
Summit Therapeutics Inc. (SMMT) financial analysis — history, returns, DCA and operating performance tools
Full SMMT Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates